EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case T-269/15: Action brought on 28 May 2015 — Novartis Europharm v Commission

ECLI:EU:UNKNOWN:62015TN0269

62015TN0269

May 28, 2015
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

24.8.2015

EN

Official Journal of the European Union

C 279/36

(Case T-269/15)

(2015/C 279/45)

Language of the case: English

Parties

Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)

Defendant: European Commission

Form of order sought

The applicant claims that the Court should:

annul the contested decision; and

order the European Commission to pay its own costs and those of Novartis.

Pleas in law and main arguments

By its present action, the applicant seeks the annulment of Commission Decision C(2015) 1977 final of 18 March 2015 granting a marketing authorisation to Pari Pharma for the medicinal product for human use ‘Vantobra — tobramycine’.

In support of the action, the applicant relies on two pleas in law.

1.First plea in law, alleging that the decision of the European Commission is unlawful in that it constitutes an infringement of the orphan market exclusivity rights of Novartis Europharm Ltd. for its product TOBI Podhaler pursuant to Article 8(1) of Regulation (EC) No. 141/2000 (1) because the period of orphan market exclusivity has not yet expired while the conditions for granting a derogation of market exclusivity pursuant to Article 8(3) of the same Regulation are not fulfilled.

2.Second plea in law, alleging that the decision of the European Commission is also unlawful because it does not contain a statement of reasons as required by Article 296 of the Treaty on the Functioning of the European Union and Article 81(1) of Regulation (EC) No. 726/2004 (2).

Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1).

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia